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Abstract
Background: We examined the association and interaction between maternal viral load and antibodies
in vertical transmission of HIV in a non-randomized prospective study of 43 HIV-1 infected pregnant
women who attended the San Juan City Hospital, Puerto Rico, and their 45 newborn infants. The women
and infants received antiretroviral therapy.
Methods: A nested PCR assay of the HIV-1 envelope V3 region and infant PBMC culture were performed
to determine HIV status of the infants. Maternal and infant plasma were tested for HIV neutralization or
enhancement in monocyte-derived macrophages.
Results: Twelve (26.7%) infants were positive by the HIV V3 PCR assay and 3 of the 12 were also positive
by culture. There was a trend of agreement between high maternal viral load and HIV transmission by
multivariate analysis (OR = 2.5, CI = 0.92, p = 0.0681). Both maternal and infant plasma significantly (p =
0.001 for both) reduced HIV replication at 10-1 dilution compared with HIV negative plasma. Infant plasma
neutralized HIV (p = 0.001) at 10-2 dilution but maternal plasma lost neutralizing effect at this dilution. At
10-3 dilution both maternal and infant plasma increased virus replication above that obtained with HIV
negative plasma but only the increase by maternal plasma was statistically significant (p = 0.005). There
were good agreements in enhancing activity in plasma between mother-infant pairs, but there was no
significant association between HIV enhancement by maternal plasma and vertical transmission.
Conclusion: Although not statistically significant, the trend of association between maternal viral load and
maternal-infant transmission of HIV supports the finding that viral load is a predictor of maternal-infant
transmission. Both maternal and infant plasma neutralized HIV at low dilution and enhanced virus
replication at high dilution. The antiretroviral treatments that the women received and the small sample
size may have contributed to the lack of association between HIV enhancement by maternal plasma and
vertical transmission.
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Background
The rate of HIV-1 infection has been increasing rapidly
among women of childbearing age. At the end of 2003
women accounted for 50% of adults living with HIV/AIDS
worldwide [1]. Consequently, the number of pediatric
AIDS cases due primarily to perinatal (peripartum or
intrapartum) transmission is rapidly increasing. Mother-
to-child transmission accounts for more than 90% of all
HIV infections in infants and children worldwide. In 2003
an estimated 2.1 million children under 15 years were liv-
ing with HIV/AIDS [1]. Zidovudine (ZDV) given as either
an intensive or short course regimen significantly reduces
perinatal transmission [2,3]. However, because of its cost,
ZDV is not always available in poorer countries of the
world. Successful use of nevirapine therapy in preventing
perinatal transmission offers hope for more affordable
treatment for poor women worldwide [4,5]. However, in
2003, only one in ten pregnant women was offered serv-
ices for preventing mother-to-child HIV transmission [1].
Further, whether treated with ZDV or nevirapine, a por-
tion of HIV-positive women still transmit virus to their
offspring vertically and the problem of maternal-infant
transmission through breast milk remains unsolved.
Therefore, there is need for continued studies of viral and
immunological factors associated with maternal-infant
transmission of HIV so that other effective and affordable
strategies to prevent transmission may be developed.
Although some studies show no association between the
presence of HIV neutralizing antibodies in maternal sera
and the risk of perinatal transmission [6,7], other studies
report a reduction in the risk of vertical transmission in
pregnant women whose sera contain neutralizing anti-
bodies to HIV [8]. A number of studies have indicated
lower transmission rates from infected pregnant women
with high antibody titer or with high affinity/avidity anti-
body to conserved portion of HIV-1 glycoprotein 41 [9],
to the CD4 binding site [10] or the V3 loop of glycopro-
tein 120 [11,12], and to the p24 Gag protein [13]. Other
studies have reported that non-transmitting mothers
more frequently have such antibodies to their own virus
than do transmitting mothers and that transmitting moth-
ers rarely have neutralizing antibody against their own
children's isolates [14,15]. In contrast, a study by St.
Louis, et al. [16] found no evidence that anti-V3 loop anti-
body protected against perinatal transmission. Further, a
study by Lallemant, et al. [17] showed that mothers with
higher antibody titers to peptides corresponding to the V3
region of gp120 and the immunodominant domain of
gp41 had a higher risk of perinatal transmission. The
authors hypothesized that women who display the broad-
est antibody response to V3 may be experiencing the
greatest viral turnover [18] which could make them more
at risk for transmitting virus to their offspring.
In contrast to neutralizing antibodies, non-neutralizing
antibodies may enhance HIV infection by binding to the
virus and facilitating its uptake by cell types that carry
immunoglobulin (Fc) or complement receptors. Antibod-
ies that enhance HIV replication in vitro by either Fc
gamma receptor- or complement receptor-mediated
endocytosis (Fcγ R-ADE or C'-ADE) have been identified
in sera from HIV-1-infected individuals [19-25] and from
many gp120-vaccinated volunteers [19,20]. An in vitro
study of antibody dependent enhancement (ADE) of HIV-
1 infection in human term syncytiotrophoblast cell cul-
tures suggested that both Fcγ R-ADE and C'-ADE may con-
tribute to maternal-infant transmission of HIV-1 [26].
Pancino, et al. [27], reported that mother-infant transmis-
sion of HIV was associated with maternal antibodies to
the envelope gp160 and to a highly conserved domain of
the trans-membrane glycoprotein. Mann, et al. [28],
observed that certain combinations of antibody sub-
classes occurred more frequently in mothers who trans-
mitted HIV-1 to their offspring than in non-transmitters
and suggested that ADE may occur in mother-infant trans-
mission of HIV-1. However, C'-ADE was not found to be
associated with maternal-infant transmission of HIV [29]
and the role of Fcγ R-ADE in maternal-infant transmission
has not been determined.
Maternal plasma virus load has been shown to be strongly
associated with perinatal transmission of HIV [27,30,31]
and it was reported that there is no absolute threshold of
maternal viral load below which HIV transmission does
not occur [32]. Although transmission did not occur at a
threshold below 2,000 copies/ml [18,33] or below 1000
copies/ml [34], more recent meta-analysis has demon-
strated that occasional transmission does occur below a
viral load threshold of 1,000 copies/ml [35]. Another
study indicated that viral load correlated with vertical
transmission in women at the clinical stage A1 (asympto-
matic) of infection [36].
However, the association of both viral load and enhanc-
ing activity (presumably by Fcγ R-ADE) in maternal
plasma and vertical transmission of HIV has not formerly
been examined. Thus, we examined the association of
these factors (independently and combined) in vertical
transmission using samples from mother-infant pairs
from San Juan, Puerto Rico, previously described by
Melendez-Guerrero et al [37]. Neutralization/enhance-
ment of a R5 tropic strain of HIV-1 subtype B by maternal
plasma was examined in monocyte-derived macrophage
cultures.
Results and Discussion
Study sample
A cohort of 43 HIV-1 subtype B infected pregnant women
attending antenatal clinic at the San Juan City Hospital,Virology Journal 2005, 2:15 http://www.virologyj.com/content/2/1/15
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Puerto Rico, was enrolled into a prospective study from
their first antenatal visit until delivery [37]. Eleven women
were enrolled during their first trimester, 24 during their
second trimester, and 8 during their third trimester of
pregnancy. Approximately forty-five HIV-1 infected
women gave birth at the San Juan City hospital during
1998. All of the women recruited into the study received
some form of antiretroviral therapy as detailed and refer-
enced [3,38-44] in Table 1. All of the infants were enrolled
into the study shortly after delivery and most (86%) were
also enrolled in the antiviral protocols during their first six
weeks of life (Table 1). One mother had triplets, therefore,
a total of 43 mothers and 45 infants (regarded as 45
mother-infant pairs) were enrolled.
Demographic and clinical characteristics of the mothers 
and vertical transmission
The mean age of the mothers was 24 years (range 14–38
years; Table 2). Majority of the women (88.4%) were
infected through heterosexual contact. Based on the 1993
CDC revised classification system for HIV infection and
disease progression, only 6 of the mothers (those in the
A3 and B3 categories) were classified as AIDS cases [45].
Approximately two-thirds (67.4%) of the mothers had
viral load levels below 10,000 RNA copies/ml and were
classified as having low viral loads (LVL) based on the cat-
egorization by Contopoulos-Ioannidis & Ioannidis [46].
The remaining 32.6% of mothers had viral loads above
10,000 RNA copies/ml and were classified as having high
viral loads (HVL). CD4+ T cell counts in the women
ranged from 23 to 1165 cells/mm3 of blood with a mean
count of 425 cells/mm3. Twenty-six of the 43 women
delivered their babies by normal vaginal delivery; the
remaining women had cesarean sections (Table 2).
Twelve (26.7%) of 45 infants were HIV V3 positive indi-
cating that HIV transmission had occurred (Table 2).
However, only three of these twelve infants were also HIV
culture positive. This infection rate of approximately 7.0%
observed is similar to the rate of 8.3% observed for ZDV
Table 1: Number and percent of HIV positive pregnant women and infants assigned to the different AIDS Clinical Trails Group 
(ACTG) protocols or to zidovudine (ZDV)
ACTG Protocol # Number of women (%) Dose and frequency
185 [38] 16 (37.2) Mother: ZDV according to 076 protocol [3] plus anti-HIV immune serum globulin 
(HIVIg) or immune globulin (Ig) (200 mg/kg) every 28 days followed by 1.0 mg/kg/hr 
continuous infusion during labor and delivery.
Infant: HIVIg (200 mg/kg) or normal Ig within 12 hrs of birth plus oral ZDV syrup (2.0 
mg/kg) every 6 hours after birth (beginning within 8–12 h) and continuing for 6 weeks.
249 [39] 4 (9.3) Mother: Didanosine (ddi) IV (1.6 mg/kg) on day one, during pregnancy, followed by an 
oral dose (200 mg) one week after the initial dose. Oral ddi is then administered every 
12 hrs until labor starts and every 12 hrs after delivery until 6 weeks post-partum. 
During labor and delivery patients receive a loading dose followed by continuous 
infusion.
Infant: Oral ZDV syrup (2.0 mg/kg) every 6 hours after birth and continuing to week 
6.
250 [40] 5 (11.6) Mother: ZDV plus Nevirapine (200 mg/kg) single dose during labor.
Infant: Oral ZDV syrup (2.0 mg/kg) every 6 hours after birth and continuing to week 
6 plus single dose of Nevirapine (2 mg/kg) after birth.
296 [41] 3 (7.0) Mother: ZDV as in protocol 185.
Infant: Oral ZDV syrup (2.0 mg/kg) every 6 hours after birth and continuing to week 
6.
316 [42] 9 (20.9) Mother: Nevirapine (200 mg oral dose) or the corresponding placebo during delivery 
plus ZDV (as in 076).
Infant: ZDV perinatal prophylaxis (2.0 mg/kg) plus single 2.0 mg/kg oral dose of 
Nevirapine or Nevirapine placebo administered between 48 and 72 hrs of life.
324 [43] 3 (7.0) Mother: ZDV before and after delivery as is usual but oral administration of ZDV 
(300 mg) every 3 hrs, 3 doses total during delivery.
Infant: Oral ZDV syrup (2.0 mg/kg) every 6 hours after birth and continuing to week 
6.
332 [44] 1 (2.3) Mother: Stravudine (d4T, 30–40 mg) during pregnancy and 0.05 mg/kg/hr during 
delivery in combination with 3TC 150 mg followed by 150 mg during delivery.
Infant: Stravudine (d4T, 1 mg/kg) single dose on day 35–42, in combination with 3TC 
(2.0 mg/kg/dose).
ZDV [3] 2 (4.7) Mother: ZDV (2.0 mg/kg) every 28 days followed by 1.0 mg/kg/hr continuous infusion 
during labor.
Infant: Oral ZDV syrup (2.0 mg/kg) every 6 hours after birth and continuing to week 
6.Virology Journal 2005, 2:15 http://www.virologyj.com/content/2/1/15
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treated mothers and infants in the 076 study [4]. Based on
the V3 PCR results an equal number of mothers with low
and high viral load (6 in each group) transmitted HIV to
their infants. The mean log viral load of transmitting
mothers 3.77 + 0.31 (median = 3.77) was higher than of
the non-transmitting mothers 3.54 + 0.15 (median =
3.44) but the difference was not statistically significant (p
= 0.474). This is probably due to the small sample size.
The mothers of the three infants who were HIV culture
positive all had high viral load levels (484,703, 11,642
and 10,220 RNA copies/ml) but the levels in two of the
three were close to the 10,000 RNA copies/ml cut-off
value used to distinguish LVL from HVL. Since perinatal
transmission occurs mostly at or during delivery, the viral
load in the genital tract (which may be similar to maternal
plasma level) [47] may be an important determinant in
maternal-infant transmission.
The mothers of HIV V3 positive infants had a non-signifi-
cantly higher mean CD4+ T count (526 cells/mm3,
median = 508 cells/mm3) compared to non-transmitting
mothers (mean CD4+ T count of 413 cells/mm3; median
= 336 cells/mm3). Maternal CD4 cell counts have been
shown to be a less effective predictor of transmission of
HIV than viral load [18]. Further, most of the women in
the study (86%) had CD4+T cell counts above the 200
cells/mm3 level which is used to define AIDS. Only one of
the three women whose infants were HIV culture positive
had AIDS (CD4 = 149 cells/mm3). The other two women
had CD4 counts of 510 and 538 cells/mm3.
Table 2: Age, source of infection, clinical status and transmission 
outcome for HIV-positive mothers
Variable Number (%)
Age of mothers (years)a
< 25 14 (32.6)
25–30 12 (27.9)
> 30 16 (37.2)
Missing 1 (2.3)
Source of infection
Heterosexual contact 38 (88.4)
IV drug use 3 (7.0)
Unknown 2 (4.6)
Clinical status (CDC classification 45)
A1 11 (25.6)
A2 14 (32.6)
A3 1 (2.3)
B1 2 (4.6)
B2 10 (23.3)
B3 5 (11.6)
Viral load (copies/ml)b
<10,000 (range 83–9,078) 29 (67.4)
≥  10,000 (range 10,220–484,703) 14 (32.6)
Mode of delivery
Vaginal 26 (60.5)
Cesarean 17 (39.5)
Transmission outcome
V3 PCR+ Infants 12 (26.7)
V3 PCR- Infants 33 (73.3)
Culture+ Infants 3c (6.7)
Culture- Infants 42 (93.3)
aMean age 24 years (range 14–28 years)
bMean viral load 28,112 copies/ml (range = 83 – 484,703 copies/ml)
cHIV infection confirmed by PCR and culture
Table 3: Neutralization/enhancement of HIV infection by plasma from 12 transmitter and 33 non-transmitter mothers and 12 HIV V3 
positive and 33 HIV V3 negative infants
Plasma Dilution and effect Transmitter mothers 
Number (%)
Non-transmitter mothers 
Number (%)
HIV V3+ infants Number 
(%)
HIV V3- infants Number 
(%)
10-1
Neutralized 11 (92) 31 (94) 11 (92) 30 (91)
Enhanced 0 (0) 0 (0) 0 (0) 0 (0)
No change 1 (8) 2 (6) 1 (8) 3 (9)
10-2
Neutralized 9 (75) 25 (76) 7 (58) 23 (70)
Enhanced 1 (8) 2 (6) 2 (17) 1 (3)
No change 2 (17) 6 (18) 3 (25) 9 (27)
10-3
Neutralized 8 (67) 19 (58) 4 (33) 9 (27)
Enhanced 0 (0) 5 (15) 4 (33) 7 (21)
No change 4 (33) 9 (27) 4 (33) 17 (52)Virology Journal 2005, 2:15 http://www.virologyj.com/content/2/1/15
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Neutralization/enhancement of HIV treated with maternal 
and infant plasma
The effect of plasma (at 10-1 to 10-3 dilutions) from the
mothers (transmitters and non-transmitters) and infants
(HIV V3+ and HIV V3-) on HIV replication was examined
in the neutralization/enhancement assay (Table 3). HIV
p24 antigen in culture fluids was determined using the
coulter p24 antigen assay kit (Coulter, Miami FL) accord-
ing to the manufacturer's instructions. The mean value of
HIV p24 antigen by dilution was calculated from seroneg-
ative samples. The percent change (increase or decrease)
in p24 antigen of the maternal or infant plasma from the
mean of the seronegative samples was calculated. Neutral-
ization was defined as 70% or greater reduction in HIV
p24 antigen in cultures treated with HIV positive plasma
compared with cultures treated with HIV negative plasma.
Enhancement was defined as 100% or greater increase in
p24 antigen in cultures treated with HIV positive plasma
compared to the p24 level in cultures treated with HIV
negative plasma. Traditionally enhancement of HIV in
PBMC cultures has been defined as a 1.5 to 2.5-fold or
greater increase in virus replication as a result of treatment
with immune sera [21,25,48]. Table 3 shows that at 10-1
dilution, over 90% of plasma samples from both groups
of mothers (transmitters/non-transmitters) and infants
(HIV V3+/ HIV V3-) neutralized HIV. At 10-2 dilution the
percentages of plasma that neutralized HIV dropped to
approximately 75% for both groups of mothers and to
58% and 70% for HIV V3+ and HIV V3- infants respec-
tively. The percentages again dropped at 10-3 dilution to ≤
67% for mothers and ≤  33% for infants (Table 3). Chi-
square or Fisher's exact test were used to compare the pro-
portion of plasma from transmitter versus non-transmit-
ter mothers and between HIV V3+ and HIV V3- infants
that neutralized, enhanced or resulted in no change in
HIV replication. No significant differences were found.
The mean percent change in p24 antigen and standard
errors for mothers and infants were plotted for each group
by plasma dilution (Figure 1). The Wilcoxon signed-
ranked test was used to determine whether the percent
change was significantly different from zero. Both the
maternal and infant plasma significantly (p = 0.001 for
both groups) reduced HIV replication at low (10-1) dilu-
tion when compared with HIV negative sera (Figure 1). At
10-2 dilution the infant plasma still significantly (p =
0.001) reduced virus replication, but the maternal plasma
lost neutralizing activity (Figure 1). At 10-3 dilution, the
maternal plasma significantly increased virus replication
(p = 0.005) above seronegative plasma and the infant
plasma showed a non-significant increase (88%) in HIV
replication (Figure 1). These findings of neutralization by
plasma of HIV positive individuals at low dilutions and
enhancement at higher dilutions are similar to data
published by Jolly and Weiss [49], which showed that
neutralizing and enhancing antibodies can occur simulta-
neously in sera of HIV-infected individuals. If neutralizing
antibody is present, enhancement is seen only at high
dilutions, whereas, if only enhancing antibody is present,
enhancement is observed without, or at low, plasma/
serum dilutions.
Enhancing activity in plasma from mothers and infants
Sixty-nine percent (31/45) of plasma from mother-infant
pairs were also tested in the neutralization/enhancement
assay at higher dilutions (10-4 to 10-6). Examination of
enhancing activity in plasma of mothers and infants
showed that there were good agreements (60% or greater)
in enhancement status between mother-infant pairs. For
example, at 10-4 dilution, the plasma of 7 infants of 9
mothers (78%) whose plasma enhanced HIV replication
also exhibited enhancement, and at 10-6 dilution, the
plasma of 8 infants of 10 mothers (80%) whose plasma
enhanced HIV replication also exhibited enhancement
(data not shown). Comparison of p24 antigen between
transmitter and non-transmitter mothers or their infants
at 10-4 to 10-6 dilutions showed no significant difference
between the two groups of mothers or infants. The lack of
association of enhancing activity and HIV transmission in
this study is similar to the findings for C'-ADE by Gras, et
al. [29]. We examined complement-independent (pre-
sumably Fcγ R-mediated antibody dependent) enhance-
ment in primary human macrophages because we
thought that this type of enhancement would be more rel-
evant to HIV clinical disease and transmission. Fcγ R-medi-
ated enhancement is characteristic of diseases such as
dengue and feline infectious peritonitis for which ADE
has been best demonstrated to occur [50,51]. In addition,
macrophages are important target cells for infection and
replication in vivo by most HIV-1 variants [52-54]. How-
ever, our results showed no association between enhanc-
ing activity in maternal or infant plasma and maternal-
infant transmission of HIV. The negative results could in
part be due to the various anti-retroviral protocols to
which the women were assigned.
Correlation between maternal and infant p24 antigen 
levels and maternal viral load with maternal and infant 
p24 antigen
Using Spearman's correlation, we examined the associa-
tion between maternal viral load and enhancing activity
in vertical transmission of HIV by using mothers' charac-
teristics (viral load and p24 antigen value) and the infants'
p24 antigen values. A correlation matrix showed a posi-
tive association between mothers' p24 antigen values and
those of their infants (Table 4). However, low positive or
no associations were found between maternal viral load
and maternal p24 antigen values at low dilutions (10-1 –
10-3) and low negative associations at higher dilutions
(10-4  – 10-6). There were low positive associationsVirology Journal 2005, 2:15 http://www.virologyj.com/content/2/1/15
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between maternal viral load and the p24 antigen values of
their infants at low dilutions (10-1 – 10-3) and low nega-
tive correlations at higher dilutions except at 10-5 dilution
(Table 4). However, none of the values was statistically
significant.
Maternal viral load and enhancing antibodies as predictors 
of vertical transmission of HIV
Univariate analysis of type of treatment, stage of HIV dis-
ease, method of delivery and CD4+ T cell count of the
mothers indicated no significant association with vertical
transmission of HIV (p > 0.05). The combined effect of
maternal viral load and enhancing antibodies as potential
Neutralization/enhancement of HIV-1BaL by maternal and infant plasma diluted 10-1 – 10-3 Figure 1
Neutralization/enhancement of HIV-1BaL by maternal and infant plasma diluted 10-1 – 10-3. Virus replication (determined by 
p24 antigen (pg/ml) in culture fluids collected 2–4 days post-infection) is compared to replication of virus treated with plasma 
from HIV-1 seronegative (sn) women. The data represent the average of all maternal and infant samples. Two independent 
infections were conducted with each sample in duplicate (4 replicates) for each of 43 maternal and 45 infant plasma. Maternal 
and infant plasma significantly reduced HIV replication (p = 0.001 for both) at 10-1 dilution compared to HIV negative sera. 
Infant plasma also significantly reduced HIV replication (p = 0.001) at 10-2 dilution. At 10-3 dilution maternal plasma significantly 
increased HIV replication (p = 0.005) above HIV negative sera and infant plasma showed a non-significant increase (88%) in HIV 
replication.
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risk factors for the vertical transmission of HIV-1 was
examined in a multivariable model. Log viral load was
treated as a continuous variable in the model and
enhancement was categorized as enhancement versus
neutralization. There was a trend of association between
maternal viral load and transmission of HIV-1 so that the
higher the viral load, the more likely mothers were to
transmit HIV-1 to their infants (OR= 2.5, CI= 0.93 – 6.67,
p = 0.0681). This is in agreement with other studies dis-
cussed earlier that show viral load as a predictor of mater-
nal-infant transmission [27,30,31]. The non-significant
result in this study is probably due to the small sample
size. Also, twice as many mothers (29) in this study had
low plasma HIV RNA levels (<10,000 RNA copies/ml)
compared to those with high viral load levels (14 moth-
ers). The preponderance of women with low viral load
levels may be the result of the effect of the different
antiretroviral protocols that the women were given during
pregnancy. Whereas Dickover, et al. [30] showed that
women given zidovudine during gestation showed an
eight-fold median decrease in plasma HIV RNA levels (p <
0.001), Sperling, et al., [32] have shown that ZDV treat-
ment had only a minimal effect in decreasing maternal
HIV RNA levels. In this study all of the women except one
(given stravudine) received ZDV treatment and in most
cases ZDV was given along with one other anti-retroviral
drug or with HIVIg (Table 1). There was no significant
association between enhancing activity (based on p24
antigen values) in the plasma of mothers who transmitted
HIV-1 to their infants based on the HIV V3+ status of the
infants (OR = 0.92, CI = 0.41 – 2.07, p = 0.8492).
Conclusion
In agreement with published data, multivariate analysis
showed a trend of association between maternal viral load
and maternal-infant transmission of HIV. The non-signif-
icant difference in the mean log viral load of transmitting
and non-transmitting mothers is probably due to the
small sample size. No significant associations were found
between HIV antiretroviral treatment protocols, classifica-
tion of HIV disease, method of infant delivery and CD4+
T cell count of the mothers and vertical transmission of
HIV. Both maternal and infant plasma significantly neu-
tralized HIV infection at low (10-1) dilution and enhanced
virus replication at higher dilution (10-3). Neutralizing
and enhancing antibodies can occur together in the blood
of HIV positive individuals and the neutralizing effect can
be lost at high plasma dilution.
There were good agreements in the neutralizing or
enhancing activity of the plasma from mothers-infant
pairs. That is, when plasma of the mothers neutralized or
enhanced HIV infection, their infants' plasma showed
similar activity. However, there was no significant associ-
ation between virus enhancement by maternal plasma
and vertical transmission of HIV. Thus, enhancing activity
in plasma of these HIV-infected mothers was not a domi-
nant factor in vertical transmission of HIV.
Methods
Collection, processing and testing of maternal and infant 
blood samples for HIV
Blood samples were taken from the mothers during each
trimester of pregnancy and during delivery. Blood sam-
ples from the infants were collected from the umbilical
cord at birth and at 1–2, 3–4 and 5–12 months. Blood was
collected in vacutainer tubes containing ACD anticoagu-
lant and centrifuged at 2500 rpm for 15 minutes. The
plasma was stored frozen (-20°C) for use in maternal viral
load and HIV neutralization/enhancement assays. The
remaining blood was diluted in phosphate-buffered
saline (PBS) pH 7.4 and processed by Ficoll-hypaque den-
sity gradient for cell isolation. For virus isolation, one mil-
lion cells from each mother or infant were co-cultured
Table 4: Correlation (Spearman) of maternal and infant p24 antigen levels and maternal viral load with maternal and infant p24 
antigen
Plasma dilution p24 antigen (M vs I) Correlationa log
(p-value)b
MVL and Mp24 Correlationc log 
(p-value)b
MVL and Ip24 Correlationd log 
(p-value)b
10-1 0.412 (0.005) 0.12 (0.448) 0.09 (0.562)
10-2 0.59 (0.0001) 0.18 (0.249) 0.11 (0.473)
10-3 0.72 (0.0001) 0.14 (0.355) 0.04 (0.832)
10-4 0.40 (0.028) -0.15 (0.423) -0.16 (0.394)
10-5 0.75 (0.0001) -0.10 (0.581) 0.31 (0.091)
10-6 0.69 (0.0001) -0.34 (0.064) -0.31 (0.089)
M = mother; I = infant; MVL = maternal viral load; Mp24 = maternal p24 antigen; Ip24 = infant p24 antigen
aSpearman correlation coefficient between log values of maternal and infant p24 antigen.
bp-value to test for statistically significant correlation.
cSpearman correlation coefficient between log values of maternal viral load and maternal p24 antigen.
dSpearman correlation coefficient between log values of maternal viral load and infant p24 antigen.Virology Journal 2005, 2:15 http://www.virologyj.com/content/2/1/15
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with HIV seronegative donor cells previously stimulated
by PHA as described in the ACTG virology manual [55].
The remaining cells (105) were stored frozen at -85°C. The
HIV status of the infants was determined using a nested
PCR assay of the HIV-1 envelope variable (V3) region as
previously described [37,56]. This V3 PCR assay was con-
ducted in duplicates and repeated on the infant samples at
1–2 months, 3–4 months and 5–11 months. Culture for
HIV was repeated on infant samples collected at 3, 6 and
12 months and all except 3 infants were culture negative.
Determination of maternal viral load
HIV RNA copies in maternal plasma was determined by
the amplicor HIV monitor test (Roche Diagnostics,
Branchwater, NJ, USA) at the Puerto Rico ACTG-certified
laboratory [37]. A 142 base-pair sequence in the HIV gag
gene was amplified by RT-PCR for viral load determina-
tion. The mean log viral load was calculated and com-
pared between transmitting and non-transmitting
mothers to determine the effect of maternal viral load on
HIV vertical transmission.
Preparation and titration of HIV-1BaL for the 
neutralization/enhancement assay
HIV-1BaL stock was prepared in primary macrophages as
reported previously by Jolly [57]. Briefly, HIV-1BaL super-
natant fluid (1 × 104.6 TCID50/ml) obtained from the NIH
AIDS Research and Reference Reagent Program was used
to inoculate fresh cultures of macrophages grown on 75
ml tissue culture flasks. The cultures were washed 24
hours later and incubated with fresh media. Supernatant
fluids were harvested at 7 and 14 days post-infection, clar-
ified by centrifugation at 1800 rpm for 10 minutes and
used as stock virus for these studies. The stock contained
5 × 105 TCID50/ml.
Neutralization/enhancement assay
A neutralization/enhancement assay was conducted using
maternal or infant samples and HIV-1BaL. Maternal
plasma samples collected during the third trimester of
pregnancy were used in these assays since most prenatal
HIV infections occur in the third trimester [58]. Briefly,
10-fold dilutions of heat inactivated (56°C for 30 min)
plasma samples were mixed 1:1 with 103 TCID50/ml of
virus and pre-incubated at 37°C for 30 min. The mixtures
were then inoculated into replicate cultures of monocyte-
derived macrophages as prepared previously [57] in 8 well
chamber slides and incubated at 37°C for 6 hours in a 5%
CO2 incubator. The inocula were removed and the cells
washed, and incubated with fresh media for up to 8 days.
Culture supernatant fluids were then collected on days 2,
4, 6, and 8 and tested for p24 antigen using the Coulter
assay (Coulter, Miami, FL, USA). Cultures treated with
HIV-negative sera were used as controls. All maternal and
infant plasma samples were tested at three 10-fold dilu-
tions; 69% of samples were tested up through six 10-fold
dilutions. Two independent assays were conducted for
each maternal or infant plasma sample and each sample
was run in duplicate on each assay (4 replicates).
Statistical analysis
Descriptive statistics such as mean, median, range were
calculated to summarize maternal characteristics such as
viral load, CD4+ T cell count and p24 antigen levels. The
number of HIV vertical transmission among infants was
summarized and the univariate association of maternal
characteristics, such as, treatment (type of antiretroviral
therapy), stage of disease based on the 1993 CDC classifi-
cation [45], method of delivery (C-section vs. vaginal),
and CD4+ T cell count, with HIV transmission in infants
was evaluated using the Fisher's exact test. The simultane-
ous effect of maternal viral load and p24 levels on infant
transmission was evaluated using the logistic regression
model. Odds ratio and 95% confidence intervals were cal-
culated for the effect of both factors in the model.
Correlation between maternal versus infant p24 antigen
levels and between maternal viral load and maternal or
infant p24 antigen levels was evaluated using the Spear-
man's correlation coefficient. Enhancement, decrease
(neutralization), or no change in p24 levels compared to
seronegative control was assessed for mother-infant pairs.
The distribution of virus p24 antigen was compared
between transmitting vs. non-transmitting mothers and
between HIV V3+ infants and HIV V3- infants using
Fisher's exact test.
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